Cretostimogene Grenadenorepvec May be ‘Attractive’ Option for NMIBC

Commentary
Video
Conference|Society of Urologic Oncology Annual Meeting (SUO)

Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.

Treatment with cretostimogene grenadenorepvec yielded a high complete response (CR) rate in a population of patients diagnosed with high-risk, Bacillus Calmette Guerin (BCG)–unresponsive non-muscle invasive bladder cancer (NMIBC), according to Mark D. Tyson, II, MD, MPH.

In a conversation with CancerNetwork® during the 2023 Society of Urologic Oncology (SUO) Annual Meeting, Tyson, a urologic oncologist of the Department of Urology at Mayo Clinic in Phoenix, Arizona, discussed how cretostimogene appears to demonstrate favorable efficacy in the context of other nonsurgical standards of care in the space such as nadofaragene firadenovec-vncg (Adstiladrin) and pembrolizumab (Keytruda).

Cretostimogene grenadenorepvec was assessed as part of the phase 3 BOND-003 trial (NCT04452591) in patients with high-risk, BCG-unresponsive NMIBC, the interim results of which were read out at the meeting. In a population of 116 patients, investigators reported a CR rate of 75.7% (95% CI, 63.0%-85.0%). Of these responses, 74.4% lasted for a minimum of 6 months. Additionally, the 3-month and 6-month CR rates, respectively, were 68.2% and 63.6%.

Transcript:

This is an interim analysis that compares favorably to the 2 current nonsurgical co-standards, nadofaragene and pembrolizumab. In terms of the complete response rate, the 76% CR rate at any time point compares favorably to the 51% observed with nadofaragene, [as well as] the 41% observed with pembrolizumab. And then the 6-month CR rate of 64% compares favorably with the 41% observed for nadofaragene and the 36% observed for pembrolizumab.

Now, these are interim results; it's really hard to compare across studies. I'm not necessarily saying that cretostimogene monotherapy is better, but I am saying that it does appear to compare favorably, and I do think it will be a really attractive option for many patients looking to preserve their bladder.

Reference

Tyson M, Uchio E, Jong-Kil N, et al. First results from BOND-003, a phase 3 study of intravesical cretostimogene grenadenorepvec monotherapy for patients with high-risk BCG- unresponsive non-muscle invasive bladder cancer. Presented at: 2023 Society of Urologic Oncology Annual Meeting; November 28-December 1, 2023; Washington, DC; LBA3396.

Recent Videos
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
START is the largest early phase oncology network in the community-based setting, according to Geraldine O’Sullivan Coyne, MD, MRCPI, PhD.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content
Shebli Atrash, MD, believes the future for treatment in multiple myeloma, as well as solid tumors and beyond, includes immune therapies.

Defining the Role of Immune Therapy in Multiple Myeloma

Roman Fabbricatore
August 9th 2025
Article

Shebli Atrash, MD, believes the future for treatment in multiple myeloma, as well as solid tumors and beyond, includes immune therapies.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Mitomycin Exhibits Durable Responses in Recurrent, Low-Grade NMIBC

Roman Fabbricatore
August 7th 2025
Article

Adverse reactions in the phase 3 ENVISION trial were largely mild to moderate in severity, and serious reactions occurred in 12% of those with NMIBC.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Leading experts gathered in Orlando, FL, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.

National ICE-T Conference Aims to Make CAR T Safer and More Available

Tim Cortese
August 2nd 2025
Article

Leading experts gathered in Orlando, Florida, to discuss the current and future state of cellular therapy in oncology at the 2025 ICE-T Symposium.

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.

CAR T-Cell Therapies Show Superior Efficacy, Safety in Multiple Myeloma

Tim Cortese
August 1st 2025
Article

Barry Paul, MD, believes cilta-cel, anito-cel, and arlo-cel are some of the most promising CAR T-cell therapies in the multiple myeloma space.